Aarti Drugs Ltd (AARTIDRUGS) — Board Meeting | 26 September 2026 (3 announcements)

Aarti Drugs reported consolidated revenue of Rs. 2,568 crores for FY26, up 7% from Rs. 2,403 crores in FY25, with PAT rising 16% to Rs. 312 crores. EBITDA margin improved to 12.9% from 12.1%, driven by volume growth and margin expansion. The company completed Rs. 600 crores of capex, including greenfield facilities at Sayakha and Tarapur, to boost backward integration and regulated market sales. Export revenue now accounts for 38% of total, with 73% of growth targeted toward regulated markets in FY26-FY27. R&D investment reached Rs. 66 crores, supporting 30+ new API developments and expansion into oncology and complex formulations. The AGM presentation highlighted strategic shifts toward premium APIs, regulated markets, and ESG compliance, with sustainability reports published for FY24-25.

Aarti Drugs announced board changes at its September 26, 2026 AGM: Uday Patil retired as Whole-time Director, Nilesh Patil was appointed as Whole-time Director, Adhish Patil became Managing Director effective October 1, 2026, and several directors were reappointed for five-year terms starting June 1, 2027 and March 29, 2027. The filing confirms no SEBI disqualifications and compliance with independence criteria.

Aarti Drugs held its 41st AGM on September 26, 2026 via video conference with 93 shareholders present. The meeting covered approval of audited financials for FY2025-26, retirement of director Uday Patil, and appointments of Nilesh Patil as director and managing director, along with reappointments of Harshit Savla, Harit Shah, Hasmukh Dedhia, Sandeep Joshi, and Ajit Venugopalan. Shareholders raised operational queries addressed by CFO. Remote e-voting remained open for 30 minutes post-meeting, with scrutiny results to be posted within two working days on company and NSDL websites.